As reported in Mergermarket's Deal Dimensions series titled Life lines: Life sciences M&A and the rise of personalised medicine, 94 per cent of life sciences companies are planning an acquisition in the next year, with more than two-thirds (70 per cent) of respondents targeting personalised medicine.
Reed Smith will host a launch event regarding the report in their New York office on Tuesday, December 1st, from 12:00 PM ET – 1:00 PM ET. Report contributors including LSHI attorney Carol Loepere, Diane Frenier and Brian Miner will lead the informal, interactive discussion of the report's findings over lunch. Discussion questions will include:
- What are the main drivers behind the sector's pursuit for cross-border deals?
- What are the challenges faced in executing those deals?
- How may advances in personalized medicine change the face of the industry?
To register for the event, please click here.
This article is presented for informational purposes only and is not intended to constitute legal advice.
